Proposal to list desmopressin tablets, progesterone capsules and mesalazine granules

Medicines

Consultation Closed

PHARMAC is seeking feedback on a proposal for listings in Section B and Part II of Section H of the Pharmaceutical Schedule through a provisional agreement with Pharmaco (NZ) Ltd.

In summary, this proposal would result in:

  • Desmopressin tablets being funded, subject to Special Authority restrictions, for patients who have primary nocturnal enuresis or cranial diabetes insipidus and where the subsidised nasal preparations are contraindicated and (in the case of nocturnal enuresis) an enuresis alarm cannot be used;
  • Progesterone capsules being funded, subject to Special Authority restrictions, for the prevention of pre-term labour where the patient has a short cervix or has a history of pre-term birth; and
  • Mesalazine granules being funded, under Special Authority restrictions, for patients who are under the age of 16 and unable to swallow tablets.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by Friday, 28 June 2013 to:

Christine Chapman
Therapeutic Group Manager
PHARMAC

PO Box 10 254
Wellington 6143

Email: Christine.Chapman@pharmac.govt.nz

Fax:     04 460 4995

All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.